General Info

Headquartered in Cambridge, Mass., Biogen Idec specializes in the field of biotechnology. Its core capabilities include drug discovery, research and development. The company s focus is the development of products related to oncology, neurology and immunology. Among the company s products are treatments for B-cell, non-Hodgkin s lymphomas; a treatment for relapsing forms of multiple sclerosis; and a treatment for psoriasis and psoriatic arthritis. In addition, the company has several licensed and dedicated bulk-manufacturing facilities engaged in protein manufacturing. James C. Mullen has been the chief executive officer of Biogen Indec for more than two years. He has been with the drug and biotechnology company for over 17 years. Mullen earned a BS degree from Rensselaer Polytech, and a MBA from Villanova. The company maintains research centers in Cambridge, Mass., and San Diego. Biogen Idec has additional offices in Canada, Australia, Japan and Europe, including international headquarters in Zug, Switzerland. The company currently employs approximately 3,400 people worldwide.